Co-DiagnosticsNASDAQ: CODX

SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21. FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relationships, and for strengthening business ties with the global medical device and equipment market, with exhibitors from 116 countries and more than 15,000 expected professional attendees.

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY , June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use. Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received.

Co-Diagnostics, Inc., a molecular diagnostics company with a patented platform for developing molecular diagnostic tests, will release its first quarter 2024 financial results on May 9, 2024, after the market closes. The Company will also hold a conference call and webcast at 4:30 p.m. on the same day.

Co-Diagnostics, Inc. (CODX) Q4 2023 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Operator Hello. Welcome to the Co-Diagnostics Third Quarter 2023 Earnings Conference Call.

SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2023 results on Thursday, November 9, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.10 per share a year ago.

SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2023 results on Thursday, August 10, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Theodore O'Neill - Litchfield Hills Research Operator Good afternoon and welcome to the Co-Diagnostics' First Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded today.